The funding of orphan medicines in the UK
| Autor: | John Spoors, Steve Bojakowski |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Actuarial science
Leadership and Management Project commissioning Cost effectiveness business.industry Health Policy media_common.quotation_subject Market access Nice Excellence Value for money Clinical value Medicine business computer health care economics and organizations media_common Healthcare system computer.programming_language |
| Zdroj: | British Journal of Healthcare Management. 20:384-391 |
| ISSN: | 1759-7382 1358-0574 |
| DOI: | 10.12968/bjhc.2014.20.8.384 |
| Popis: | The increasing number of patients suffering from rare diseases is creating greater demand for treatments. This, combined with an incentivised regulatory framework, is resulting in a significant number of novel but expensive treatments coming to market. Payers are becoming concerned by the cumulative impact of these treatments and are starting to question the clinical value and justification for their high price. One of the key issues driving this is the widening gap between regulatory data requirements and the information required by payers to determine whether or not the new treatment offers value for money for the healthcare system. This paper seeks to explore the funding challenges for UK payers and highlights that the eculizumab (Soliris, Alexion) review by the National Institute for Health and Care Excellence (NICE) will provide a strong indication of how these drugs will be reviewed and funded in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|